Comprehensive analysis of PD‐L1 in non‐small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue

enthalten in: Thoracic Cancer | 2022

von Wang, C. | Huang, K. | Chang, H. | +6

Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib : A real‐world study

enthalten in: Thoracic Cancer | 2021

von Wang, C. | Lai, C. | Chang, Y. | +4

Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer

enthalten in: Thoracic Cancer | 2020

von Chu, C. | Chiu, T. | Wang, C. | +10

Front‐line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC : The role of systemic progression control

enthalten in: Thoracic Cancer | 2019

von Huang, S. | Huang, A. | Wang, C. | +9